Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV ferric carboxymaltose versus oral iron in children with inflammatory bowel disease and iron deficiency anemia
NL-OMON44995Recruiting
- Sponsor
- Atrium Medical Corporation
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ferric carboxymaltose and Iron in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD), sponsored by Atrium Medical Corporation. Primary endpoint: Proportion of patients with at least 15% increase in 6-minute walking distance. Started Sep 2014; status: recruiting.
02
Drugs
ferric carboxymaltoseIron
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON44995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44995.